• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers

The Plymouth Meeting, Pa.-based firm said a Phase 1 study of Zika vaccine GLS-5700 'induced high levels of binding antibodies in 100% of participants.'
By ARMIE MARGARET LEE Oct 05, 2017 | 09:20 AM EDT
Stocks quotes in this article: INO, ACAD, BIIB

Shares of Inovio Pharmaceuticals Inc. (INO) jumped 9.4% to $7.09 in premarket trading on Thursday, Oct. 5, on positive safety and and immune response results from its Phase 1 study of Zika vaccine GLS-5700.

The study "induced high levels of binding antibodies in 100% of participants," Inovio said. "Robust neutralizing antibody and T cell immune response were also observed in vaccinated subjects."

The results are published in the New England Journal of Medicine. Plymouth Meeting, Pa.-based Inovio -- a holding in TheStreet's Stocks Under $10 portfolio -- is developing GLS-5700 with Seoul-based GeneOne Life Science Inc and academic collaborators from the U.S. and Canada.

Meanwhile, shares of Acadia Pharmaceuticals Inc. (ACAD) were up 5.7% to $41.38 after the San Diego firm said  Wednesday it has launched a Phase 3 study of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis.

The company also said the FDA has given breakthrough therapy designation to pimavanserin for dementia-related psychosis.

  • Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

The FDA in April of last year approved pimavanserin for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

In other news, Biogen Inc. (BIIB) said new data from the Phase 3 Endear study showed that "earlier initiation of treatment with Spinraza (nusinersen) may improve motor function outcomes in infants and children with spinal muscular atrophy (SMA)."

Cambridge, Mass.-based Biogen presented the data at the International Annual Congress of the World Muscle Society in Saint Malo, France.

Biogen shares were up 1.3% to $319.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
TAGS: Investing | U.S. Equity | Regulation | Markets | Healthcare | ETFs | Funds | Stocks | Stocks Under $10

More from Healthcare

2 Health-Related Stocks See Bits of Insider Interest

Bret Jensen
Apr 19, 2021 10:00 AM EDT

Large purchases of Cortexyme Inc. and NantHealth Inc. shares have been made by insiders recently.

UnitedHealth Group's Charts Look Strong

Bruce Kamich
Apr 16, 2021 11:35 AM EDT

Here's where traders should look to buy a pullback.

Cigna Has Made a Huge Upside Breakout

Bruce Kamich
Apr 16, 2021 10:55 AM EDT

Traders could go long CI at current levels, and we have two price objectives.

Jim Cramer: We've Got a Boom ... and a Bust

Jim Cramer
Apr 15, 2021 3:36 PM EDT

Let's look at this impossible move on the market -- and why health care could be coming off life support.

TransMedics Group's Charts Are Pointed Lower

Bruce Kamich
Apr 15, 2021 9:30 AM EDT

These charts are not pretty.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:05 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How recency bias and the Pareto Principle impact y...
  • 02:42 PM EDT PAUL PRICE

    Wednesday on Real Money Pro

    Make this stock a 'part' of your portfolio.
  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login